In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study
Tóm tắt
Bacterial infections that cause community-acquired urinary tract infections (CA-UTI) and upper respiratory tract infections (CA-URTI) are most frequently treated empirically. However, an increase in antimicrobial resistance has become a problem when treating outpatients. This study determined the in vitro activities of oral antibiotics among 1501 pathogens from outpatients with CA-UTI and CA-URTI in medical centers during 2012 and 2013 from Argentina, Mexico, Venezuela, Russia, and the Philippines. Minimal inhibitory concentrations (MICs) were determined using broth microdilution and susceptibility defined by Clinical Laboratory Standards Institute (CLSI) and European Committee for Antimicrobial Susceptibility Testing (EUCAST) criteria. Ceftibuten (MIC50, ≤0.25 mg/L) was more potent in vitro compared to other β-lactams against Enterobacteriaceae from CA-UTI. Susceptibility to fluoroquinolones using CLSI criteria varied: Argentina and Mexico (50%), the Philippines (60%), Venezuela (70%), and Russia (80%). Fosfomycin susceptibility was >90% against Enterobacteriaceae in each country. Susceptibility among Enterobacteriaceae to trimethoprim-sulfamethoxazole was 30.6–75.6% and nitrofurantoin susceptibility also varied among the countries and was higher when EUCAST breakpoints were applied (65–>90%) compared to CLSI (52–84%). All Haemophilus influenzae isolates from CA-URTI were susceptible to ceftibuten, cefixime, cefpodoxime, and cefuroxime using CLSI breakpoint criteria. EUCAST criteria produced intermediate and resistant MIC values for these oral cephalosporins. Country-specific susceptibility variation for fluoroquinolones, macrolides, and trimethoprim-sulfamethoxazole was observed among Streptococcus pneumoniae and Streptococcus pyogenes from CA-URTI. This study demonstrated that antimicrobial susceptibility patterns varied in the five countries investigated among pathogens from CA-UTI and CA-URTI. Merck & Co. Inc., Kenilworth, New Jersey, USA.
Tài liệu tham khảo
Bantar C, Curcio D, Jasovich A, et al. Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II). Rev Chilena Infectol. 2010;27(Suppl 1):S9–38.
Bours PH, Polak R, Hoepelman AI, Delgado E, Jarquin A, Matute AJ. Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines. Int J Infect Dis. 2010;14:770–4.
Christiaens T, De Backer D, Burgers J, Baerheim A. Guidelines, evidence, and cultural factors: comparison of four European guidelines on uncomplicated cystitis. Scan J Prim Health Care. 2014;22:141–5.
Llor C, Rabanaque G, Lopez A, Cots JM. The adherence of GPs to guidelines for the diagnosis and treatment of lower urinary tract infections in women is poor. Fam Pract. 2011;28:294–9.
Rogue F, Soares S, Breitenfeld L, Figueiras A, Herdeiro MT. Influence of community parmacists’ attitudes on antibiotic dispensing behaviour: a cross-sectional study in Portugal. Clin Ther. 2014;37:168–77.
Sanchez GV, Robers RM, Albert AP, Johnson DD, Hicks LA. Effects of knowledge, attitudes and practices of primary care providers on antibiotic selection, United States. Emerg Infect Dis. 2014;20:2041–7.
Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183(Suppl 1):S1–4.
Ahmed NH, Hussain T, Biswal I. Comparison of etiological agents and resistance patterns of the pathogens causing community acquired and hospital acquired urinary tract infections. J Glob Infect Dis. 2014;6:135–6.
De Backer D, Christiaens T, Heytens S, De Sutter A, Stobberingh EE, Verschragen G. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 10 year interval. J Antimicrob Chemother. 2008;62:364–8.
Abreu AG, Marques SG, Monteiro-Neto V, Goncalves AG. Extended-spectrum β-lactamase-producing enterobacteriaceae in community-acquired urinary tract infections in Sao Luis, Brazil. Braz J Microbiol. 2013;44:469–71.
Schaeffer EM. Extended-spectrum β-lactamase-producing gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. J Urol. 2012;188:831–2.
Kimura K, Nagano N, Nagano Y, et al. High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group B streptococci with reduced penicillin susceptibility. J Antimicrob Chemother. 2013;68:539–42.
Golden AR, Rosenthal M, Fultz B, et al. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007–13. J Antimicrob Chemother. 2015;70:2199–202.
Lo DS, Shieh HH, Ragazzi SL, Koch VH, Martinez MB, Gilio AE. Community-acquired urinary tract infection: age and gender-dependent etiology. J Bras Nefrol. 2013;35:93–8.
Rocha JL, Tuon FF, Johnson JR. Sex, drugs, bugs, and age: rational selection of empirical therapy for outpatient urinary tract infection in an era of extensive antimicrobial resistance. Braz J Infect Dis. 2012;16:115–21.
Clinical Laboratory Standards Institute. 2014. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fourth Informational Supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA 19087-1898 USA.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, January 1, 2014. http://www.eucast.org/clinical_breakpoints/. Accessed 28 Jan 2014.
Clinical Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standards—Ninth Edition. CLSI document M07-A9. Wayne, PA 19087-1898 USA.
Linhares I, Raposo T, Rodriques A, Almeida A. Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: a ten-year surveillance study (2000–2009). BMC Infect Dis. 2013;13:19.
Lopez-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother. 2014;69:809–14.
Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: A 7-year surveillance study. Am J Infect Control. 2014;42:1033–8.
Cordoba G, Siersma V, Lopez-Valcarcel B, et al. Prescribing style and variation in antibiotic prescriptions for sore throat: cross-sectional study across six countries. BMC Fam Pract. 2015;16:7.
Hürlimann D, Limacher A, Schabel M, Zanetti G, Berger C, Mühlemann K, Kronenberg A, Swiss Sentinel Working Group. Improvement of antibiotic prescription in outpatient care: a cluster-randomized intervention study using a sentinel surveillance network of physicians. J Antimicrob Chemother. 2015;70:602–8.